Pharma major Lupin and its alliance partner Natco Pharma have Natco) received an approval from the United States Food and Drug Administration (U.S. FDA) for Natco’s Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection.
Eribulin Mesylate Injection is the bioequivalent to the reference listed drug (RLD) Halaven Injection of Eisai, Inc.
Eribulin Mesylate Injection is indicated for the treatment of adults with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease and unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.
Eribulin Mesylate Injection (RLD Halaven) had estimated annual sales of $43.7 million in the US (IQVIA MAT April 2026).